High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are l...

Full description

Saved in:

Bibliographic Details
Main Authors:	Metzelder, Stephan (Author) , Kröger, Michael (Author) , Reiter, Andreas (Author) , Dreger, Peter (Author)
Format:	Article (Journal)
Language:	English
Published:	November 2012
In:	Leukemia Year: 2012, Volume: 26, Issue: 11, Pages: 2353-2359
ISSN:	1476-5551
DOI:	10.1038/leu.2012.105
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1038/leu.2012.105 Verlag, Volltext: https://www.nature.com/articles/leu2012105
Author Notes:	S. K. Metzelder, T. Schroeder, A. Finck, S. Scholl, M. Fey, K. Götze, Y. C. Linn, M. Kröger, A. Reiter, H. R. Salih, T. Heinicke, R. Stuhlmann, L. Müller, A. Giagounidis, R. G. Meyer, W. Brugger, M. Vöhringer, P. Dreger, M. Mori, N. Basara, K. Schäfer-Eckart, B. Schultheis, C. Baldus, A. Neubauer, A. Burchert

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses by Metzelder, Stephan (Author)

in: Leukemia, 26 (2012), 11, Seite 2353-2359

Article (Journal)

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses by Metzelder, Stephan (Author)

Similar Items